INT302314

Context Info Confidence 0.44 First Reported 2010 Last Reported 2011 Negated 0 Speculated 0 Reported most in Body Documents 5 Total Number 5 Disease Relevance 2.22 Pain Relevance 0.33

extracellular space (SOST) extracellular region (SOST) transcription factor binding (SOST)

Anatomy Link Frequency hip 1 SOST (Homo sapiens)

Pain Link Frequency Relevance Heat antagonist 3 99.36 spinal stenosis 3 98.64 Sciatica 3 97.88 carpal tunnel syndrome 3 94.80 fibrosis 110 23.84 transdermal 22 5.00 cva 11 5.00 tolerance 6 5.00 Inflammation 4 5.00 Pain 4 5.00

Disease Link Frequency Relevance Heat Spinal Stenosis 3 98.64 Osteoporosis 142 98.26 Nerve Root Compression 3 97.88 Targeted Disruption 7 95.52 Carpal Tunnel Syndrome 6 94.80 Frailty 3 93.88 Apoptosis 3 88.48 Hypercalcemia 51 83.44 Fracture Healing 19 79.28 Postmenopausal Osteoporosis 17 71.76

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

In contrast, inhibition of sclerostin also results in significant bone formation at the periosteal surface.

Negative_regulation (inhibition) of sclerostin

1) Confidence 0.44 Published 2010 Journal Curr Osteoporos Rep Section Body Doc Link PMC2841260 Disease Relevance 0.28 Pain Relevance 0

The molecular mechanisms underlying these anabolic effects are still poorly understood, but appear to include both direct actions on osteoblastic cells as well as indirect effects such as through stimulation of IGF-1 production and downregulation of sclerostin, a physiologic antagonist of the important anabolic Wnt-?

Negative_regulation (downregulation) of sclerostin associated with antagonist and osteoporosis

2) Confidence 0.42 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.61 Pain Relevance 0.05

Preclinical studies with a sclerostin inhibitor appear to be somewhat different from those with hPTH (1–34).

Negative_regulation (inhibitor) of sclerostin

3) Confidence 0.32 Published 2010 Journal Curr Osteoporos Rep Section Body Doc Link PMC2841260 Disease Relevance 0.12 Pain Relevance 0

In summary, treatments based on inhibition of sclerostin may be a powerful way to restore bone strength of the osteoporotic skeleton in our patients and potentially to provide more efficacious protection from hip fracture than current therapies.

Negative_regulation (inhibition) of sclerostin in hip associated with frailty

4) Confidence 0.32 Published 2010 Journal Curr Osteoporos Rep Section Body Doc Link PMC2841260 Disease Relevance 1.01 Pain Relevance 0.24

A deficiency of sclerostin results in increased Wnt signaling and high bone mass.

Negative_regulation (deficiency) of sclerostin

5) Confidence 0.07 Published 2011 Journal Journal of Osteoporosis Section Body Doc Link PMC3010683 Disease Relevance 0.21 Pain Relevance 0.04

General Comments

This test has worked.